Psoriasis

Ben Lockshin, MD, FAAD, covered ways in which GLP-1 RAs can be utilized when treating psoriatic disease.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Celltrion's Yuflyma gains full FDA interchangeability, enhancing patient access and affordability for various inflammatory conditions.

FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.

A recent analysis reveals safety profiles of apremilast and deucravacitinib for psoriasis, highlighting unique adverse events and long-term monitoring needs.

Ascletis Pharma's investigational new drug application for ASC50 gains FDA clearance for a phase 1 trial for mild to moderate psoriasis.

Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.

Psoriasis significantly impacts sleep health, with diverse populations facing increased risks of sleep disorders, highlighting urgent clinical needs for tailored interventions.

Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.

GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.

New guidelines from the Genital Psoriasis Wellness Consortium highlight the significant impact of genital psoriasis on patients, emphasizing improved diagnosis and personalized treatment.

Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.

Discover the promising results of risankizumab for treating genital and scalp psoriasis, showcasing significant improvements in symptoms and quality of life.

New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.

Abrocitinib’s targeted inhibition of JAK1 offers effective control of AD, but may, in rare instances, lead to a shift in immune expression resulting in paradoxical psoriasis.

Johnson & Johnson's icotrokinra shows promising results in treating moderate plaque psoriasis, especially in challenging areas like the scalp and genitals.

The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.

Explore the potential of GLP-1 receptor agonists in psoriasis management, highlighting their immunomodulatory effects and metabolic benefits for patients.

Roflumilast foam shows significant efficacy in treating scalp and body psoriasis, enhancing patient adherence and quality of life in a recent clinical trial.

Guselkumab shows high effectiveness and safety in treating moderate to severe plaque psoriasis, enhancing quality of life in real-world Korean patients.

Younger patients with moderate to severe psoriasis exhibit risky sun exposure behaviors, raising concerns about tanning addiction and skin cancer risks.

VYNE Therapeutics paused its VYN202 trial for psoriasis due to an FDA-issued clinical hold.

Continuity with a known physician and rapid response times significantly increased patient willingness to use teledermatology.

Trials often exclude high-risk patients, limiting the real-world relevance of their safety findings.

A recent study reveals that women with psoriasis are more likely to discontinue biologic treatments, including IL-17 and IL-23 inhibitors, due to adverse events and treatment dissatisfaction.

Subcutaneous methotrexate may offer improved efficacy and patient adherence in psoriasis treatment, though it comes at a higher cost.

A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

Positive changes in DLQI scores were observed after 4 weeks of therapy as well as the 6-month follow-up.

Bio-naïve patients and those without comorbidities had the highest treatment success rates with guselkumab.